Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes-Reference-Cited by-同舟云学术

Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes

Published:2018-11-27 Issue:5 Volume:35 Page:793-804
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Blonde Lawrence¹,Anderson John E.²,Chava Pavan³,Dendy Jared A.³

Affiliation:

1. Ochsner Diabetes Clinical Research Unit, Frank Riddick Diabetes Institute, Department of Endocrinology, Ochsner Medical Center, New Orleans, LA, USA;

2. The Frist Clinic, Nashville, TN, USA;

3. Ochsner Medical Center, Department of Endocrinology, New Orleans, LA, USA

Funder

Sanofi US, Inc.

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2018.1541790

Reference62 articles.

1. Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients

2. Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expert Opinion on Optimising Type 2 Diabetes Treatment Using Fixed-Ratio Combination of Basal Insulin and GLP-1 RA for Treatment Intensification and Simplification;Diabetes Therapy;2024-06-27

2. Fixed ratio combinations GLP-1RA and basal insulin: literature review;Problems of Endocrinology;2024-02-28

3. Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA Japan;Diabetes Therapy;2024-02-16

4. Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection;Canadian Journal of Cardiology;2023-12

5. Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: The RESTORE-G real-world study;Nutrition, Metabolism and Cardiovascular Diseases;2023-11